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Abstract
Background: The use of targeted agents to impel dual inhibition of anti-apoptotic mechanisms and mTOR-
mediated pro-survival signaling in colorectal carcinoma (CRC) cell lines with KRAS or BRAF mutation has been
shown to induce apoptosis, a timely result given CRC entities harboring such mutations are in need of new
therapies. Since CRC comprises heterogeneous tumors with predominant hypoxic components, we investigated
effects of an inhibitor of anti-apoptotic Bcl-2 family proteins (ABT-737) in combination with an mTOR inhibitor
(AZD8055)—collectively referred to as combo-Rx, in hypoxic CRC cell lines.
Methods: Cell viability measures, expression of proteins implicated in apoptosis and MAPK/PI3K-AKT/mTOR
pathway signaling, and profiling of composite kinase activities were undertaken in a panel of 14 cell lines.
Results: In hypoxic conditions, combo-Rx suppressed viability of 13 of the cell lines, albeit ABT-737 did not significantly
potentiate the inhibitory effect of single-agent AZD8055 in six of the models. Hypoxic KRAS/PIK3CA-mutant HCT-116 and
HCT-15 cell lines (both with low endogenous expression of the anti-apoptotic Mcl-1 protein and showing augmented
inhibition of viability following the addition of ABT-737 to AZD8055) responded to combo-Rx by induction of apoptosis
but with the simultaneous strong Mcl-1 up-regulation and activation of MAPK/PI3K-conducted signaling. In
contrast, in hypoxic KRAS-mutant LoVo (devoid of PIK3CA mutation), BRAF/PIK3CA-mutant RKO, and wild-type
Colo320DM cell lines (all with high endogenous Mcl-1 expression and being resistant to the additional effect of
ABT-737 to AZD8055), combo-Rx did not elicit apoptotic or pro-survival responses.
Conclusions: The concurrent inhibition of anti-apoptotic proteins and mTOR-mediated signaling in hypoxic KRAS/
PIK3CA-mutant CRC cell lines resulted in pro-survival responses in parallel with the intended anti-proliferative effects, a
finding that should be of note if considering combinatory targeting of multiple pathways in this CRC entity.
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Background
Colorectal carcinoma (CRC), like most solid malignan-
cies, comprises heterogeneous tumors with predominant
hypoxic components. The adaptive tissue responses to
hypoxic stress involve increased resistance to apoptosis
(programmed cell death) as well as altered DNA damage
repair and mutation rates, and thereby genomic instabil-
ity [1–3], ultimately leading to compromised efficacy of
DNA-damaging therapies (chemotherapy and radiation).
Moreover, mutations in genes such as KRAS, BRAF, and
PIK3CA commonly result in constitutive activation of
cellular signaling mediated by mitogen-activated protein
kinases (MAPK) and phosphatidylinositol 3-kinase–pro-
tein kinase B (PI3K–AKT) [4, 5]. These pathways con-
verge at the mechanistic target of rapamycin (mTOR),
which regulates cell growth and survival [6] and makes
the mTOR complex an attractive target for CRC therapy.
Consequently, a number of mTOR inhibitors have
entered clinical trials.
There is however evidence of crosstalk between the
mTOR-conducted signaling and other signaling pathways
which will allow tumor cells to escape mTOR-inhibitory
therapy [7, 8]. Targeting of multiple pathways has therefore
been considered. Recent findings showed that the combin-
ation of the mTOR inhibitor AZD8055 with ABT-263, an
inducer of apoptosis, promoted cell death in CRC cell lines
with KRAS or BRAF mutation [9], a timely result given
CRC entities harboring these mutations are refractory to
current targeted therapies. ABT-263 and its structurally
related compound ABT-737 are potent inhibitors of the
anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w, but not of
Mcl-1, and induce apoptosis in cancer cells [10, 11]. Over-
expression of Mcl-1 is associated with resistance to ABT-
737, and inhibition of Mcl-1 has proven to sensitize cancer
cells to ABT-737 [12–14]. Interestingly, hypoxia has been
shown to promote ABT-737-mediated apoptotic cell death
in small-cell lung carcinoma, CRC, and hematologic cell
lines via down-regulation of Mcl-1 [15–17].
Since no information is available regarding the concur-
rent inhibition of anti-apoptotic proteins and mTOR-
mediated pro-survival signaling under CRC tumor hypoxia,
we investigated response to treatment with ABT-737 and
AZD8055, in this report referred to as combo-Rx, in a
panel of hypoxic CRC cell lines harboring various typical
mutations.
Methods
Cell lines, culture conditions, and reagents
Fourteen human CRC cell lines (kindly provided by Prof.
Kjersti Flatmark, Oslo University Hospital, Oslo, Norway
or purchased from the American Type Culture Collection,
Manassas, VA, USA) were first determined for mutations
in KRAS, BRAF, and PIK3CA by Ion Torrent PGM™
sequencing, and mutation profiles were in agreement to
already published data [18–20]. All cell lines except Caco-
2 were kept in RPMI 1640 medium (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 10 % fetal bovine
serum (Gibco by Life Technologies, Grand Island, NY,
USA) and 2 mM L-glutamine (GE Healthcare, PAA
Laboratories, Pashing, Austria). The Caco-2 cells were
kept in DMEM medium (Sigma-Aldrich) containing 15 %
serum. The cell lines were routinely tested and found free
of mycoplasma infection. For all assays, cells were seeded
and left to adhere overnight to reach exponential growth
at start of experiments. Cells were incubated under nor-
moxic (21 % O2) or hypoxic (0.2 % O2) conditions, the lat-
ter obtained using the hypoxic chamber Invivo2 300
(Ruskinn Technologies, Leeds, UK). The mTOR inhibitor
AZD8055, the PI3K/mTOR inhibitor BEZ235, the Bcl-2
family protein inhibitor ABT-737, and the pan-caspase
inhibitor Z-VAD (all by Selleckchem.com, SMS-gruppen,
Rungsted, Denmark) were dissolved in dimethyl sulfoxide
(Sigma-Aldrich). Control cells received the vehicle.
Cell viability assay
Depending on the cell line, 12,000-20,000 cells were
seeded per well in 96-well Costar plates (Corning Incorpo-
rated, Corning, NY, USA). Cells were given ABT-737 or
AZD8055, separately or combined, in increasing concen-
trations (0.10-10 μM; combo-Rx designates 10 μM of both
compounds), the combination of ABT-737 and BEZ235
(10 μM of both compounds), or vehicle. When expedient,
the cells were pre-treated for 45 min with Z-VAD (20 or
50 μM). Cell viability was determined after 24 or 72 h by
adding CellTiter 96®AQueous One Solution Reagent
according to the manufacturer’s instructions (the MTS
assay; Promega, Madison, WI, USA). Absorbance was
measured using Varioscan (Thermo Electron, Waltham,
MA, USA). Values were corrected for background absorb-
ance, and values for treated cells are reported as percent-
age cell viability to corresponding control cell values.
Presented results are from between three and seven inde-
pendent experiments, each plated at least in triplicate.
Western blot analysis
Cells were seeded in Nuncleon T25 flasks (Thermo Fisher
Scientific, Roskilde, Denmark) and were treated as indi-
cated, and protein lysates from both floating and adherent
cells were harvested as previously described [21]. Equal
amounts of protein (20 μg) were separated by NuPAGEBis-
Tris (Novex by Life Technologies, Carlsbad, CA, USA),
transferred by electrophoresis to Immobilon® membrane
(Millipore Corporation, Billerica, MA, USA), and probed
with antibodies against hypoxia-inducible factor type 1α
(HIF-1α; BD Transduction Laboratories, Franklin Lakes,
NJ, USA) and carbonic anhydrase IX (CAIX; kindly
provided by Prof. Silvia Pastorekova, Slovak Academy of
Sciences, Bratislava, Slovak Republic), and against Mcl-1,
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Bcl-2, Bcl-xL, caspase-3, mitogen-activated protein kin-
ase3/1 (ERK1/2), p-ERK1/2(Thr202/Tyr204), AKT, p-
AKT(Ser473), ribosomal protein S6 kinase beta-2 (S6), and
p-S6(Ser235/236) (Cell Signaling Technology, La Jolla, CA,
USA). Anti-α-tubulin (Calbiochem/EMD Chemicals Inc.,
San Diego, CA, USA) and Amido Black (Sigma-Aldrich)
total protein staining were used as loading controls. Sec-
ondary antibodies were from Dako Denmark AS (Glostrup,
Denmark). Peroxidase activity was visualized using Super-
Signal West Dura Extended Substrate (Thermo Scientific,
Rockford, IL, USA). Sufficient amount of lysate from each
sample was prepared to run three gels. The parallel blot-
ting membranes were considered identical, and different
proteins were visualized on different membranes for practi-
cality. All Western blot experiments were performed as
three biological replicates.
RNA interference
Mcl-1 expression was inhibited using short hairpin
(sh)RNA (clone ID NM_021960.3-953s1c1; Sigma-Aldrich),
and control cells were generated using non-target sequence
(product number shc002v; Sigma-Aldrich). The manufac-
turer’s instructions were followed apart from extending the
lentiviral incubation period to 48 h.
Microscopy
Cells were seeded in Nuncleon T25 flasks and treated
as indicated for up to 72 h. When expedient, the cells
were pre-treated for 45 min with Z-VAD. Phase-
contrast images were processed at the start of experi-
ment and further after 24, 48, and 72 h by Olympus
IX81 (Olympus Europa Holding GmbH, Hamburg,
Germany).
Kinase activity profiling
The Tyrosine Kinase PamChip® Array technology
(PamGene International B.V., ‘s-Hertogenbosch, The
Netherlands) enables profiling of composite tissue kinase
activities [4]. The array contains peptides that are kinase
substrates and consisting of 13 or 14 amino acids with
tyrosine residues for phosphorylation. Protein lysates used
for Western blot analysis were also incubated on the
arrays for kinase activity profiling. Substrate phosphoryl-
ation intensities were measured using the Evolve software
(PamGene International B.V.). Applying BioNavigator
software (PamGene International B.V.), endpoint signal
intensities generated from bound fluorescent anti-
phosphotyrosine antibody were converted to numerical
values. The primary array data are available in the
ArrayExpress data repository (http://www.ebi.ac.uk/
arrayexpress/experiments/E-MTAB-3870/) by accession
number E-MTAB-3870. Background signals were
subtracted, and negative signal intensities were managed
by subtracting the 1 % quantile of all data and setting the
remaining signal intensities less than 1 to the value of 1.
Data were log2-transformed before mean signal intensity
of three replicates that were analyzed for each experimen-
tal condition was calculated for each peptide substrate.
The resulting data from each type of treatment was com-
pared to the relevant control (vehicle-treated cells) for
assessment of increase or decrease in substrate phosphor-
ylation level. Substrates associated with PI3K-AKT and/or
MAPK pathways were retrieved from PathCards (http://
pathcards.genecards.org/), applying the super-pathway
definitions ‘PI3K-AKT signaling pathway’ and ‘MAPK sig-
naling pathway’.
Statistical analysis
Differences between groups were analyzed using two-tailed
Student’s t-test. p-values less than 0.05 were considered sta-
tistically significant. In the assessment of combination
effects on cell viability, we chose to evade calculations
based on median-effect equation for multiple drug interac-
tions because the ABT-737 single-agent effects did not
appear with typical dose-response curves.
Results
Inhibition of anti-apoptotic proteins or mTOR-mediated
signaling—cell viability
First, individual effects of the Bcl-2 family protein in-
hibitor ABT-737 and the mTOR inhibitor AZD8055 on
cell viability under hypoxia and normoxia at 24 h were
examined (Additional file 1: Fig. S1a). Incubation of
HCT-116, RKO, HT-29, and Colo320DM cell lines with
increasing concentrations of ABT-737 (0.10–10 μM)
had modest effects. In contrast, differential sensitivity
was observed with AZD8055 (0.10–10 μM), with HT-
29 cells being refractory and HCT-116, RKO, and
Colo320DM cells displaying suppressed cell viability in
the order of 20–60 % depending on the oxygenation
status. The intended cellular response to hypoxia was
confirmed by the time-dependent induction of HIF-1α
and its target CAIX in HCT-116 cells (Additional file 1:
Fig. S1b).
Since Faber and co-workers found that the com-
bination of ABT-263, a structurally related com-
pound to ABT-737, with AZD8055 at concentrations
of 50–500 nM for 72 h caused apoptosis in CRC cell
lines with KRAS or BRAF mutation [9], we next in-
vestigated inhibitory effects on cell viability when
combining AZD8055 at 0.10 μM with ABT-737 for
72 h. For seven tested cell lines, ABT-737 potenti-
ated AZD8055 under hypoxia in only one of five
mutant ones (of which three and two had KRAS and
BRAF mutation, respectively; one of each had also
PIK3CA mutation) but in both of the wild-type
models (Additional file 2: Tables S1a and S1b).
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Combo-Rx and hypoxic cell viability
Based on the two initial sets of results, the highest
tested concentration (10 μM) of both compounds was
chosen for further experiments. First, we investigated
viability in 14 CRC cell lines under normoxic condi-
tions (Additional file 2: Table S2). The addition of
ABT-737 significantly potentiated inhibitory effects of
AZD8055 in four of six KRAS-mutant and one of three
wild-type cell lines but in none of five BRAF-mutant
models. The findings in the two first-mentioned groups
but not in BRAF-mutant cell lines were generally in
agreement with previously reported data [9].
Specifically, we were interested in elucidating inhibi-
tory effects of combo-Rx under hypoxic conditions in
the 14 cell lines (Fig. 1). Again, single-agent ABT-737
caused limited decrease in cell viability (median decline
of 6.2 % (range,−2.0 to 19 %) across cell lines), which
was significant in five cell lines only. Incubation with
AZD8055 (by itself resulting in a median decline of
25 % (range,−7.0 to 45 %) across the cell lines) or
combo-Rx significantly suppressed cell viability in 11
and 13 of the 14 cell lines, respectively. However, as
shown in Table 1, in six of the hypoxic cell lines (one of six
KRAS-mutant, three of five BRAF-mutant, and two of three
wild-type ones), ABT-737 did not significantly potentiate
the inhibitory effect of single-agent AZD8055. Three of the
14 cell lines, two sensitive and one resistant to the add-
itional effect of ABT-737, had PIK3CA mutation. Similarly,
treatment with the PI3K/mTOR inhibitor BEZ235, which
has demonstrated anti-proliferative effects in various
models [22, 23], caused a median decline of 22 % (range,
3.5 to 47 %) in cell viability across hypoxic cell lines, which
in five of 12 cell lines was not significantly potentiated by
ABT-737 (Additional file 2: Tables S3a and S3b).
Combo-Rx—Mcl-1 and apoptotic response
Further focusing on the finding that ABT-737 was un-
able to significantly potentiate the effect of AZD8055 on
cell viability in approximately half of hypoxic cell lines
investigated and moreover, since previous studies have
shown that suppression of the anti-apoptotic Mcl-1 pro-
tein sensitizes cells to ABT-737 [12–14], Mcl-1 was
knocked down in the KRAS/PIK3CA-mutant HCT-116
cell line (with low endogenous Mcl-1 expression and be-
ing sensitive to the additional effect of ABT-737) and the
BRAF/PIK3CA-mutant RKO and wild-type Colo320DM
cell lines (both with high endogenous Mcl-1 expression
and being resistant to the additional effect of ABT-737)
(Fig. 2a). Specific knockdown of Mcl-1, though not
complete, and not of other anti-apoptotic proteins was
confirmed (Fig. 2b). As shown in Fig. 2c, Mcl-1 knock-
down significantly sensitized for inhibitory cell viability
effects by ABT-737 and combo-Rx in all three hypoxic
cell lines. Next, when the Mcl-1-repressed cell lines were
pre-treated with the pan-caspase inhibitor Z-VAD
(20 μM) in order to examine to which extent apoptosis
might account for responses, the inhibitory cell viability
effect was completely abolished in hypoxic shMcl-1
HCT-116 cells given ABT-737 or combo-Rx and partly
counteracted by combo-Rx in hypoxic shMcl-1 RKO
cells (Fig. 2d). On increasing the Z-VAD concentration
to 50 μM, no further regulatory effects were seen in the
Fig. 1 Cell viability in hypoxic colorectal carcinoma (CRC) cell lines. Fourteen CRC cell lines were treated for 24 h with ABT-737 (inhibitor of anti-
apoptotic Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor; 10 μM), or combo-Rx (10 μM of both compounds in combination) under hyp-
oxic conditions. Cell viability (measured by the MTS assay) value for each condition relative to the corresponding control cell value is shown as
mean ± SD. Statistically significant changes are indicated (asterisk, p < 0.05; cross, p < 0.01; circle, p < 0.001)
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Mcl-1-repressed RKO and Colo320DM cell lines (data
not shown). These results do not exclude the possibility
that the low levels of remaining Mcl-1 protein were able
to protect these cell lines to inhibitory effects of ABT-
737, as complete knockdown of Mcl-1 was not obtained
(Fig. 2b). Nevertheless, the data collectively indicated
two different modes of hypoxic cell viability response,
one clearly involving apoptosis (in HCT-116 cells) and
another not.
To explore the notion of non-apoptotic mechanisms
of combo-Rx effects in RKO and Colo320DM cell lines,
the three hypoxic cell lines were treated for 72 h and
inspected at 24-h intervals (Additional file 3: Fig. S2). In
HCT-116 cells, a mixture of pycnotic cells indicating
apoptosis [24] and still surface-attached cells was ob-
served at 24 h. This particular finding of a dual pheno-
type remained for the entire incubation period of 72 h
(data not shown). In the Colo320DM and RKO cell lines,
combo-Rx caused decrease in cell confluence, indicating
growth-inhibitory effects, but essentially few pycnotic
cells after 48 and 72 h, respectively. The Colo320DM
cells did not tolerate the combo-Rx drug concentrations
in hypoxia for 72 h. In neither of the two cell lines, the
growth inhibition following combo-Rx was abolished by
Z-VAD (data not shown), again arguing against the
involvement of apoptosis.
Combo-Rx—activation of hypoxic pro-survival signaling
Following the observations in hypoxic HCT-116 cells
that combo-Rx was effective in inhibiting viability but
caused both surface-attached and pycnotic cells, under-
lying mechanisms for the regulatory effects were investi-
gated. The HCT-116, RKO, and Colo320DM cell lines
from the preceding sets of experiments were comple-
mented with HCT-15 cells (KRAS/PIK3CA-mutant and
sensitive to the additional effect of ABT-737 to
ABT8055) and LoVo cells (with high endogenous Mcl-1
expression (Fig. 2a) and the only KRAS-mutant model
that was resistant to combo-Rx for viability). The five
cell lines were assessed for induction of apoptosis, as in-
dicated by cleavage of caspase-3, and for pro-survival
signaling by phosphorylation of ERK1/2 (p-ERK1/2) of
the MAPK pathway, of AKT (p-AKT(Ser473)) of the
PI3K-AKT pathway, and of S6 (p-S6) down-stream of
mTOR, and by expression of the anti-apoptotic protein
Mcl-1 (Fig. 3).
Of initial note, 24 h of hypoxic incubation in itself
(i.e., of control cells) inhibited Mcl-1 expression in the
majority of the cell lines. Although levels of caspase-3
were also lower under hypoxic compared to normoxic
conditions in both cell lines that were sensitive to the
additional effect of ABT-737 to ABT8055 (HCT-116
and HCT-15), cleaved caspase-3 was observed after
24 h of hypoxic combo-Rx. As expected, this apoptotic
feature could not be detected in the three resistant cell
lines (LoVo, RKO, and Colo320DM). Next, under nor-
moxia, ABT-737 treatment caused Mcl-1 up-regulation
and p-S6 induction as a consequence, and these re-
sponses were counteracted by the addition of AZD8055
(i.e., under combo-Rx compared to ABT-737 treatment
alone). These observations were in agreement with pre-
viously reported data [9]. Under hypoxia also, Mcl-1
up-regulation by ABT-737 alone was generally seen in
all cell lines with mutations (HCT-116, HCT-15, LoVo,
and RKO); however, a striking response followed the
addition of AZD8055 to ABT-737. The two models that
showed potentiation with combo-Rx (HCT-116 and
HCT-15; both also with PIK3CA mutation) demon-
strated a further strong induction of Mcl-1 and p-S6
and also of p-ERK1/2. In contrast, hypoxic combo-Rx
did not cause any uniform pattern of regulation of
these selected pro-survival factors in the resistant cell
lines. Specifically, in the KRAS-mutant LoVo cell line
(devoid of PIK3CA mutation), the addition of AZD8055
counteracted the effects of ABT-737 on Mcl-1 and p-
S6, exactly like under normoxia. The hypoxic BRAF/
PIK3CA-mutant RKO cells showed Mcl-1 and p-S6 re-
sponses similar to but not as strong as those of the
HCT-116 and HCT-15 models. And in the wild-type
Colo320 cell line, hypoxic combo-Rx did not cause
Mcl-1 alteration nor was p-S6 detected. In summary,
Table 1 Cell viability of hypoxic human colorectal carcinoma
cell lines
Cell line Mutations ABT-737 AZD8055 combo-Rx p-value
HCT-116 KRAS, PIK3CA 89.4 ± 19.1 73.0 ± 10.9 46.1 ± 13.7 0.0016
HCT-15 KRAS, PIK3CA 92.7 ± 2.31 89.7 ± 3.79 68.0 ± 10.4 0.028
SW620 KRAS 80.6 ± 8.91 77.8 ± 13.4 28.0 ± 3.46 <0.001
SW480 KRAS 99.0 ± 3.46 71.0 ± 12.1 41.7 ± 8.39 0.026
HCC2998 KRAS 85.3 ± 6.41 96.0 ± 14.2 37.0 ± 8.37 <0.001
LoVo KRAS 101 ± 10.3 64.0 ± 7.21 58.7 ± 8.50 0.45
RKO BRAF, PIK3CA 95.0 ± 12.8 65.3 ± 3.79 68.3 ± 5.03 0.46
KM20L2 BRAF 100 ± 4.62 90.9 ± 7.38 80.7 ± 6.63 0.019
WiDr BRAF 98.3 ± 1.71 99.0 ± 3.46 68.7 ± 21.6 0.074
HT-29 BRAF 97.3 ± 7.48 86.0 ± 8.54 79.0 ± 11.4 0.44
CO-115 BRAF 86.3 ± 2.89 69.7 ± 2.52 58.7 ± 2.52 0.0059
Caco-2 wild-type 90.4 ± 17.0 60.1 ± 15.3 42.3 ± 17.9 0.068
Colo320DM wild-type 102 ± 6.73 54.9 ± 4.56 54.9 ± 5.46 1.0
SNU-C1 wild-type 83.0 ± 11.4 107 ± 20.0 68.0 ± 15.9 0.023
From between three and seven independent experiments, each at least
with triplicate setups, mean ± SD cell viability values were calculated in
percentage of values from the corresponding controls (vehicle-treated
cells). Treatments (24-h incubations): ABT-737 (inhibitor of anti-apoptotic
Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor; 10 μM), combo-Rx
(10 μM of both compounds in combination). Difference in values from cells
given AZD8055 or combo-Rx was compared by two-tailed Student’s t-test.
Mutation status is indicated for each cell line
Risberg et al. BMC Cancer  (2016) 16:531 Page 5 of 11
Fig. 2 (See legend on next page.)
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the results highlighted the possibility of dual apoptotic
and pro-survival responses in KRAS/PIK3CA-mutant
CRC cells responding under hypoxic conditions with
augmented inhibition of viability to the addition of
ABT-737 to AZD8055.
Combo-Rx—activation of hypoxic kinase signaling
Following the intriguing results that phosphorylation of a
discrete number of MAPK/mTOR-signaling mediators was
induced by combo-Rx in hypoxic KRAS/PIK3CA-mutant
cell lines, we applied the Tyrosine Kinase PamChip® Array
to assess HCT-116 kinase activities more broadly. The
KRAS-mutant HCC2998 cell line, which also responded to
hypoxic combo-Rx with augmented inhibition of viability
but did not harbor PIK3CA mutation (Table 1), and the
non-responding wild-type Colo320DM cell line, in which
p-ERK1/2 and p-S6 had not been detected (Fig. 3), were
analyzed for comparison.
As depicted in Fig. 4 and detailed in Additional file 4:
Table S4, ABT-737 inhibited the kinase activity in both
hypoxic and normoxic HCT-116 cells. Intriguingly, lysates
from hypoxic HCT-116 cells given AZD8055 or combo-
Rx generated strong phosphorylation of the majority of
the array peptides and not explicitly substrates associated
with the MAPK or PI3K-AKT signaling pathways. In par-
ticular, peptides representing proteins involved in the an-
giogenic response to hypoxia (such as PDGFRB, EPOR,
ANXA2, CTTN1, MET, PXN, and PECAM1) and MAPK/
PI3K-conducted signaling in particular (RASA1, RAF1,
PIK3R1, and PDPK1) were highly phosphorylated (log2
fold-change >2.0; Additional file 4: Table S4). In normoxic
HCT-116 cells, treatment with AZD8055 generally
Fig. 3 Expression of proteins implicated in apoptosis and MAPK/PI3K-AKT/mTOR pathway signaling. The five cell lines were treated for 24 h with
ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor; 10 μM), or combo-Rx (10 μM of both compounds in
combination), and protein expression was examined by Western blot analysis. Cleaved capspase-3 (17 kDa) is a marker for apoptosis. *, unspecific band.
ERK1/2, AKT, and S6 are mediator proteins of MAPK, PI3K-AKT, and mTOR signaling. Mcl-1 is an anti-apoptotic Bcl-2 family protein. Abbreviation: p,
phosphorylation. For transparency, the dotted lines indicate where membranes had been cut as explained in the Methods section. The experiments
were performed three times each
(See figure on previous page.)
Fig. 2 The anti-apoptotic Mcl-1 protein and hypoxic cell viability. a Expression of Mcl-1 in a panel of human colorectal carcinoma cell lines, as
illustrated by Western blot analysis. The experiment was performed twice. b Three parental cell lines were treated with short hairpin (sh)RNA of
Mcl-1 and a non-target control sequence (shc002v), and expression of anti-apoptotic proteins was examined by Western blot analysis. The experiment
was performed at least three times for each of the cell line groups. c The parental and the shc002v and shMcl-1 versions of the three cell lines were
treated for 24 h with ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor; 10 μM), or combo-Rx (10 μM of both
compounds in combination) under hypoxic conditions. Cell viability (measured by the MTS assay) values for treated cells relative to the corresponding
controls (mean ± SD) are shown. Statistically significant differences between cell line versions are indicated (asterisk, p < 0.05; cross, p < 0.01). d The
same cell line entities were treated for 24 h under hypoxic conditions with ABT-737, AZD8055, or combo-Rx alone or following pre-treatment for
45 min with the pan-caspase inhibitor Z-VAD (20 μM), as indicated. Cell viability values relative to the corresponding control values are shown as mean
± SD. Statistically significant differences between treatment groups are indicated (asterisk, p < 0.05; cross, p < 0.01)
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suppressed kinase activity, while combo-Rx caused in-
creased phosphorylation (but by log2 enhancement <2.0)
of a limited number of substrates. In contrast, kinase ac-
tivity of HCC2998 cells, whether hypoxic or normoxic,
was predominantly repressed by all treatment conditions,
while Colo320DM kinase activity was basically
unchanged.
Discussion
A number of recent findings [4, 9, 16, 17] led us to investi-
gate the effects of ABT-737, an inhibitor of anti-apoptotic
Bcl-2 family proteins, in combination with the mTOR
inhibitor AZD8055 in a panel of 14 hypoxic CRC cell
lines. Combo-Rx (i.e., the combination treatment) sup-
pressed viability of 13 of the cell lines, albeit ABT-737 did
not significantly potentiate the inhibitory effect of single-
agent AZD8055 in six of the models. On further mechan-
istic investigations, the hypoxic KRAS/PIK3CA-mutant
HCT-116 and HCT-15 cell lines (both with low endogen-
ous expression of the anti-apoptotic Mcl-1 protein and
showing augmented inhibition of viability following the
addition of ABT-737 to AZD8055) responded to combo-
Rx by induction of apoptosis (as assessed by various ex-
perimental approached in the HCT-116 cells) and with the
simultaneous strong Mcl-1 up-regulation and activation of
MAPK/PI3K-conducted signaling. A ubiquitous activation
of hypoxic kinase signaling by combo-Rx was also con-
firmed in the HCT-116 cells. In contrast, in hypoxic
KRAS-mutant LoVo, BRAF/PIK3CA-mutant RKO, and
wild-type Colo320DM cell lines (all with high endogenous
Mcl-1 expression and being resistant to the additional ef-
fect of ABT-737 to AZD8055), combo-Rx did not elicit
apoptotic or pro-survival responses. Collectively, this data
revealed complex responses to the concurrent inhibition of
anti-apoptotic proteins and mTOR-mediated signaling in
hypoxic CRC cell lines, where pro-survival responses were
elicited in parallel with the intended anti-proliferative ef-
fects in KRAS/PIK3CA-mutant entities in particular, a find-
ing that should be of note if considering the combinatory
targeting of multiple pathways in CRC treatment.
As recently shown [9], when combined with ABT-263
(structurally related to ABT-737), AZD8055 via the specific
suppression of Mcl-1 sensitized CRC cell lines with KRAS
or BRAF mutation to undergo apoptosis, a timely result as
such CRC entities are refractory to current targeted therap-
ies. In vitro studies have shown promising treatment effects
of both types of agents, but concerns have been raised with
regard to lacking therapeutic efficacy of mTOR inhibitors
in solid tumors [11, 25]. Both AZD8055 and the anti-
apoptotic inhibitors ABT-263 and ABT-737 have reached
early-phase clinical trials. However, only a few reports exist
on the use of ABT-263 or ABT-737 in hypoxic tumor
models [15, 16], and as pointed out by Harrison and co-
workers [16], whether Mcl-1 is up- or down-regulated may
be cell type- and oxygen concentration-dependent. To our
knowledge, little information is currently available on
Fig. 4 Ex vivo kinase substrate phosphorylation. The color map visualizes normalized log2-transformed signal intensities from kinase
substrate arrays incubated with lysates from the three cell lines treated for 24 h with ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM),
AZD8055 (mTOR inhibitor; 10 μM), or combo-Rx (10 μM of both compounds in combination). As quantified and categorized by the color codes, red
corresponds to higher and blue to lower substrate phosphorylation levels relative to levels from the corresponding control cells (vehicle-treated). Substrates
associated with PI3K-AKT and/or MAPK signaling pathways were retrieved from PathCards (http://pathcards.genecards.org/), applying the super-pathway
definitions ‘PI3K-AKT signaling pathway’ and ‘MAPK signaling pathway’. The identity of each peptide substrate, vertically in order from top to bottom, is
given in Additional file 4: Table S4
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effects of AZD8055 or other mTOR inhibitors under hyp-
oxic conditions, with the exception of BEZ235 which has
been shown to sensitize hypoxic breast and prostate cancer
cells to radiation [26, 27].
Invariably, CRC comprises heterogeneous tumors with
predominant hypoxic components [4], which is import-
ant to take into consideration with established as well as
novel therapies. The present study showed that combo-
Rx significantly suppressed viability of hypoxic CRC
cells, but in six of 14 cell lines there was no additional
inhibitory effect of ABT-737 to that of single-agent
AZD8055. A similar finding was obtained with the com-
bination of ABT-737 and BEZ235 (potentiation was not
seen in five of 12 cell lines) and when AZD8055 in a
lower concentration of 0.10 μM was given together with
ABT-737 (four of seven hypoxic cell lines were resistant
to an additional effect of the anti-apoptotic inhibitor). In
the five cell lines where mechanistic investigations were
undertaken (the KRAS-mutant HCT-116, HCT-15, and
LoVo models and the BRAF/PIK3CA-mutant RKO and
wild-type Colo320DM cells), combo-Rx under hypoxic
conditions caused dual phenotypic responses in terms of
concurrent apoptotic and pro-survival effects in the
HCT-116 and HCT-15 cell lines, as demonstrated
through the specific examination of the anti-apoptotic
Mcl-1 protein, microscopy of cell cultures, and both tar-
geted and comprehensive analysis of kinase signaling.
Importantly, both of these cell lines also harbor PIK3CA
mutation. These findings suggest that CRC cancers with
co-occurring KRAS and PIK3CA mutations, which is not
a frequent entity [5], may be particularly susceptible to
parallel apoptotic and pro-survival effects with this com-
bination treatment.
The MAPK and PI3K-AKT signaling pathways merge at
the mTOR complex, which promotes cell survival through
phosphorylation of S6 and the resulting increase in Mcl-1
protein translation [28]. Intriguingly, in hypoxic HCT-116
and HCT-15 cells, combo-Rx strongly increased expres-
sion of Mcl-1 and p-S6, which under normoxia and in
agreement with previously reported data [9] showed the
opposite response following the addition of AZD8055 to
ABT-737. The Tyrosine Kinase PamChip® Array approach
enabled the investigation of more general kinase activity
responses. Using this technology, ABT-737 was shown to
repress kinase activities known to be important for CRC
survival in hypoxic HCT-116 cells. Under normoxic con-
ditions, ABT-737 treatment has been shown to sensitize
CRC and rhabdomyosarcoma cell lines for AZD8055-
directed apoptosis [9, 29]. It is therefore notable that in
our experimental setups, a number of array substrates as-
sociated with MAPK/PI3K-conducted signaling (RASA1,
RAF1, PIK3R1, and PDPK1) were phosphorylated by
lysates from hypoxic HCT-116 cells given combo-Rx.
Moreover, array substrates reflecting proteins that are
fundamental in the angiogenic response to hypoxia, par-
ticularly PDGFRB, were also highly phosphorylated. In
angiogenesis, PDGFR is required for the formation of a
functional pericyte coverage of regenerating endothelium
within the tumor stroma [30]. Importantly, the KRAS-mu-
tant HCC2998 cell line, which was sensitive to combo-Rx
for viability but devoid of PIK3CA mutation, and the re-
sistant wild-type Colo320DM model, showed repressed or
unchanged global kinase activities to the experimental
perturbations. Again, the findings indicate a particular
susceptibility of KRAS/PIK3CA-mutant CRC entities to
unfavorable responses to the combined inhibition of anti-
apoptotic proteins and mTOR signaling. Of final note, in
the context of interpreting the ex vivo kinase substrate
data, some important considerations should be kept in
mind [4]. One is that hypoxia elicits a multitude of adap-
tive signaling responses, which as such are challenging to
portray, and another is that phosphorylation of each indi-
vidual substrate on the kinase target array reflects the net
result of an extensive network of multiple kinase activities.
Conclusions
To conclude, under hypoxia, which is an important fea-
ture of CRC tumors and a main mechanism of therapy
resistance, the apparently rational approach of combining
ABT-737 for inhibition of anti-apoptotic proteins with the
mTOR inhibitor AZD8055 [9] in CRC cell lines with co-
occurring KRAS and PIK3CA mutations revealed complex
responses of pro-survival effects elicited in parallel with
apoptosis. Recognizing the obvious limitation that CRC
cell lines do not fully reflect the heterogeneity of this dis-
ease with regard to mutation profiles or the dynamic
nature of tumor oxygenation status, more extensive pre-
clinical studies are required for further elucidation of
responses to this kind of combination treatment. Still,
from a clinical perspective, and particularly with tumor
hypoxia posting a demand for more tailored therapies
[31], caution should be practiced on implementation of
combinatory strategies.
Additional files
Additional file 1: Fig. S1. Cell viability of hypoxic colorectal carcinoma
(CRC) cell lines. a. Four CRC cell lines were treated for 24 h with the indicated
concentrations of ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins) or
AZD8055 (mTOR inhibitor) under normoxic or hypoxic culture conditions. Cell
viability (measured by the MTS assay) value for each condition relative to the
corresponding control cell (vehicle-treated) value is shown as mean ±
SD from at least three independent experiments, each plated at least in
triplicate. Statistically significant changes are indicated (asterisk, p < 0.05;
cross, p < 0.01; circle, p < 0.001). b. Cultures of the CRC cell line were left
in the hypoxic chamber at 0.2 % O2 and harvested after the indicated time
periods. Expression of the hypoxia-inducible factor type 1α (HIF-1α) and its
target gene carbonic anhydrase IX (CAIX) was examined by Western blot
analysis, with α-tubulin expression as loading control, and with 24 h of
normoxia and 4 h of 100 μM CoCl2 exposure in normoxia to generate
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negative and positive biological controls for HIF-1α expression, respectively.
(DOCX 369 kb)
Additional file 2: Table S1a. Cell viability of normoxic colorectal
carcinoma cell lines. From at least three independent experiments, each
at least with triplicate setups, mean ± SD cell viability values were
calculated in percentage of values from the corresponding controls
(vehicle-treated cells). Treatments (72-h incubations): ABT-737 (inhibitor of
anti-apoptotic Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor;
0.10 μM), both compounds in combination. Difference in values from
cells given AZD8055 or the combination treatment was compared by
two-tailed Student’s t-test. Mutation status is indicated for each cell line.
Table S1b. Cell viability of hypoxic colorectal carcinoma cell lines. From
at least three independent experiments, each at least with triplicate
setups, mean ± SD cell viability values were calculated in percentage of
values from the corresponding controls (vehicle-treated cells). Treatments
(72-h incubations): ABT-737 (inhibitor of anti-apoptotic Bcl-2 family
proteins; 10 μM), AZD8055 (mTOR inhibitor; 0.10 μM), both compounds
in combination. Difference in values from cells given AZD8055 or the
combination treatment was compared by two-tailed Student’s t-test.
Mutation status is indicated for each cell line. Table S2. Cell viability of
normoxic colorectal carcinoma cell lines. From between three and seven
independent experiments, each at least with triplicate setups, mean ± SD
cell viability values were calculated in percentage of values from the
corresponding controls (vehicle-treated cells). Treatments (24-h incubations):
ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), AZD8055
(mTOR inhibitor; 10 μM), both compounds in combination (combo-Rx).
Difference in values from cells given AZD8055 or combo-Rx was compared
by two-tailed Student’s t-test. Mutation status is indicated for each cell line.
Table S3a. Cell viability of normoxic colorectal carcinoma cell lines. From at
least three independent experiments, each at least with triplicate setups, mean
± SD cell viability values were calculated in percentage of values from the
corresponding controls (vehicle-treated cells). Treatments (24-h incubations):
ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), BEZ235 (PI3K/
mTOR inhibitor; 0.10 μM), both compounds in combination. Difference in
values from cells given BEZ235 or the combination treatment was compared
by two-tailed Student’s t-test. Mutation status is indicated for each cell line.
Table S3b. Cell viability of hypoxic colorectal carcinoma cell lines. From at
least three independent experiments, each at least with triplicate setups, mean
± SD cell viability values were calculated in percentage of values from the
corresponding controls (vehicle-treated cells). Treatments (24-h incubations):
ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), BEZ235
(PI3K/mTOR inhibitor; 0.10 μM), both compounds in combination. Difference
in values from cells given BEZ235 or the combination treatment was
compared by two-tailed Student’s t-test. Mutation status is indicated for each
cell line. (DOCX 36 kb)
Additional file 3: Fig. S2. Microscopy of cellular phenotypes under hypoxia.
The three colorectal carcinoma cell lines were given combo-Rx (combination
of 10 μM ABT-737, an inhibitor of anti-apoptotic Bcl-2 family proteins, and
10 μM AZD8055, an mTOR inhibitor) for 72 h under hypoxia and inspected by
phase-contrast microscopy at 24-h intervals. Control cells received vehicle only.
Floating pycnotic cells in medium are indicated by arrows. Scale bars: 50 μm.
(DOCX 1104 kb)
Additional file 4: Table S4. Tyrosine Kinase PamChip® Array
substrates—phosphorylation levels. The color map visualizes normalized
log2-transformed signal intensities from kinase substrate arrays incubated
with lysates from the three colorectal carcinoma cell lines treated for 24 h
with ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM),
AZD8055 (mTOR inhibitor; 10 μM), or combo-Rx (10 μM of both compounds
in combination). Red corresponds to higher and blue to lower substrate
phosphorylation levels relative to levels from the corresponding control
cells. a Retrieved from UniProtKB/SwissProt (http://www.uniprot.org/).
b Position(s) of the tyrosine phosphorylation site(s) within the protein.
c Retrieved from PathCard (http://pathcards.genecards.org/). Super-pathway
definitions were ‘PI3K-AKT signaling pathway’ and ‘MAPK signaling pathway’.
(DOC 536 kb)
Abbreviations
CAIX: Carbonic anhydrase IX; CRC: Colorectal carcinoma; ERK1/2: Mitogen-
activated protein kinase 3/1; HIF-1α: Hypoxia-inducible factor type 1α; MAPK:
Mitogen-activated protein kinases; mTOR: Mechanistic target of rapamycin;
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